Systemic sclerosis [scleroderma] M34- 1 circumscribed scleroderma (#N#ICD-10-CM Diagnosis Code L94.0#N#Localized scleroderma [morphea]#N#2016 2017 2018 2019 2020 2021... 2 neonatal scleroderma (#N#ICD-10-CM Diagnosis Code P83.88#N#Other specified conditions of integument specific to newborn#N#2018... More ...
The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: limited scleroderma and diffuse scleroderma. A disease that is marked by hardening and thickening of skin, connective tissue that surrounds other tissues and organs, and blood vessels.
ICD-9-CM is the official system of assigning codes to diagnoses and procedures associated with hospital utilization in the United States. The ICD-9 was used to code and classify mortality data from death certificates until 1999,...
Systemic sclerosis [scleroderma] M34- >. A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin.
ICD-10 code M34 for Systemic sclerosis [scleroderma] is a medical classification as listed by WHO under the range - Diseases of the musculoskeletal system and connective tissue .
Scleroderma is caused by the immune system attacking the connective tissue under the skin and around internal organs and blood vessels. This causes scarring and thickening of the tissue in these areas.
This form of scleroderma can occur at any age but is most common in women of childbearing age. It occurs in around 30 persons per million population per year and there are an estimated 125,000 active cases in the United States and perhaps 2.5 million worldwide. It is the most fatal of all the rheumatologic diseases.
There is no treatment that can cure or stop the overproduction of collagen that is characteristic of scleroderma. But a variety of treatments can help control symptoms and prevent complications.
In general, patients with limited scleroderma have a normal life expectancy. Some have problems with their GI tract, especially heartburn; severe Raynaud's and musculoskeletal pain; and a small subset can develop pulmonary hypertension that can be life-threatening.
Although it most often affects the skin, scleroderma also can affect many other parts of the body including the gastrointestinal tract, lungs, kidneys, heart, blood vessels, muscles and joints.
Patients with systemic sclerosis (SSc) have worse health-related quality of life than patients with other systemic rheumatic diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), a Korean study found.
Two drugs are currently FDA approved to treat lung scarring, or pulmonary fibrosis, that occurs as a result of scleroderma: nintedanib and tocilizumab.
The most promising drugs are mycophenolate mofetil or cyclophosphamide with or without antithymocyte globulin.
Other pharmacological agents that may cause scleroderma include paclitaxel, pentazocine, cocaine, appetite suppressants and D-penicillamine. Paclitaxel is a cytotoxic alkaloid used in cancer chemotherapy. Pentazocine is an analgesic medication.
Avoid eating two to three hours before bed- time. Avoid foods that may aggra- vate symptoms such as citrus fruits, tomato products, greasy fried foods, coffee, garlic, onions, peppermint, gas-producing foods (such as raw peppers, beans, broccoli or raw onions), spicy foods, carbonated beverages and alcohol.
However, similar features of hard and thick skin can be seen in other conditions which are often referred to as “scleroderma mimics”. These mimics include eosinophilic fasciitis, nephrogenic systemic fibrosis, scleromyxedema, and scleredema among others.
Symptoms of scleroderma may include:Thickening and swelling of the fingers.Pale fingers that may become numb and tingle when exposed to cold or stress, known as Raynaud's phenomenon.Joint pain.Taut, shiny, darker skin on large areas, which can cause problems with movement.More items...
Middle age, female sex, positive family history and exposure to silica are risk factors for scleroderma. Infectious agents, alcohol and cigarette smoking are not risk factors for scleroderma development.
Common symptoms of scleroderma may include painful joints (arthralgia), morning stiffness, fatigue, and/or weight loss. The intermittent loss (triggered by cold temperatures) of blood supply to the fingers, toes, nose, and/or ears (Raynaud's phenomenon) is an early and frequent complaint of people with scleroderma.
This type of scleroderma is typically accompanied by shortness of breath, a persistent cough, and the inability to perform routine physical activities. End-stage scleroderma often causes pulmonary fibrosis and/or pulmonary hypertension, both of which can be life-threatening.
Sometimes called systemic sclerosis, the subcategories (all classified to code 710.1) include the following: • Diffuse cutaneous systemic sclerosis — affects skin of the fingers, hands, arms, legs, face, neck, and trunk.
Two subcategories of localized scleroderma (both included in code 701.0) are as follows: • Morphea — oval-shaped, thick patches appear on the skin, which are white in the middle with a purple border. This form of scleroderma most likely occurs on the torso but may also appear on the arms, legs, or forehead.
This form of scleroderma most likely occurs on the torso but may also appear on the arms, legs, or forehead. • Linear scleroderma — results in bands or streaks of hardened skin on one or both of the arms or legs or on the forehead. Systemic scleroderma (710.1) affects not only the skin but also blood vessels and major organs.
The condition, which is not contagious, infectious, or cancerous, may range in seriousness from mild to life threatening. There is currently no cure for scleroderma, and the autoimmune disorder may be fatal if left untreated. Signs and Symptoms.
Blood tests may be ordered to check for elevated blood levels of certain antibodies. The physician may also choose to perform a skin biopsy. Although there is no known cure and treatment will not stop the overproduction of collagen, medications will treat symptoms and complications of sc leroderma.
Systemic sclerosis [scleroderma] M34- 1 A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension. 2 A chronic multi-system disorder of connective tissue. It is characterized by sclerosis in the skin, the lungs, the heart, the gastrointestinal tract, the kidneys, and the musculoskeletal system. Other important features include diseased small blood vessels and autoantibodies. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: limited scleroderma and diffuse scleroderma. 3 A disease that is marked by hardening and thickening of skin, connective tissue that surrounds other tissues and organs, and blood vessels. 4 A rare, chronic disease characterized by excessive deposits of collagen in the skin or other organs 5 Systemic disorder of the connective tissue; manifested by hardening and thickening of the skin, by abnormalities involving the microvasculature and larger vessels, and by fibrotic degenerative changes in various body organs including the heart, lungs, kidneys, and gastrointestinal tract.
A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition. A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues.
A rare, chronic disease characterized by excessive deposits of collagen in the skin or other organs. Systemic disorder of the connective tissue; manifested by hardening and thickening of the skin, by abnormalities involving the microvasculature and larger vessels, and by fibrotic degenerative changes in various body organs including the heart, ...
Scleroderma, localized. Clinical Information. A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. Localized scleroderma typically affects the skin, with formation of patches or lines of thick and unyielding tissue;
The 2022 edition of ICD-10-CM L94.0 became effective on October 1, 2021.